PhagoGen was established in July 2024 under the value of promoting human welfare through healthy living.
PhagoGen aims to develop atherosclerosis therapeutics based on substances promoting efferocytosis.
In the long term, PhagoGen aims to develop innovative new drugs based on technology controlling phagocytosis, analysis and diagnostics preventing diseases, and healthcare devices promoting heathy living.